Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.
Department of Clinical and Molecular Bio-Medicine, Sections of Hematology, Oncology and General Pathology, University of Catania - Ferrarotto Hospital, Via Citelli 6, 95124 Catania, Italy. fsematol@tiscali.it
Fabio
F
Stagno
Paolo
P
Vigneri
Alessandra
A
Cupri
Stefania
S
Stella
Francesco
F
Di Raimondo
D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D028761:Withholding Treatment
D010879:Piperazines; D011743:Pyrimidines